Willow Biosciences (TSX: WLLW) (OTCQX: CANSF) today announced its completion of the first commercial scale fermentation run of its first cannabinoid for market, cannabigerol (“CBG”). “We are very pleased with the yield and quality of our first commercial scale fermentation run of CBG,” said Trevor Peters, Willow’s president and chief executive officer. “I think it is important to take a moment to reflect on all that we have achieved in just under two years as a public company. In this time, we built a world class industrial R&D team, demonstrated proof of concept for production of cannabinoids through fermentation, attracted reputable development partners like Albany Molecular Research Inc., and produced our first commercial scale batch of CBG. On the capital markets side, we have completed three successful financings bringing in supportive and sophisticated shareholders who have provided us with a healthy balance sheet to execute on our business plan. We are now starting the next phase of Willow’s lifecycle, which will involve supplying commercial quantities of cannabinoids to customers and recognizing revenue therefrom.”
To view the full press release, visit https://ibn.fm/Di3vF
About Willow Biosciences Inc.
Willow is a Canadian biotechnology company based in Vancouver, British Columbia that produces high-purity, plant-derived compounds that provide building blocks for the global pharmaceutical, health and wellness, and consumer packaged goods industries. Willow’s current focus is in the production of cannabinoids for the treatment for pain, anxiety, obesity, brain disorders, among other significant indications. Willow’s science team has a proven track record of developing manufacturing technologies for high-purity compounds in pain and cancer treatments. Willow’s manufacturing process creates a consistent, scalable and sustainable product that allows for the discovery and development of new life-changing drugs. For more information, visit the company’s website at www.WillowBio.com.
NOTE TO INVESTORS: The latest news and updates relating to WLLW are available in the company’s newsroom at http://ibn.fm/WLLW
About MissionIRNewsBreaks
MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
[email protected]
Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html
